Prolynx
San Francisco, United States · Founded 2010 · $70.0M raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2010
- Business Model
- B2G
- Website
- prolynxinc.com
- Total Funding
- $70.0M
- Last Round
- $70.0M Series ANov 2025
- Rounds
- 1
About
ProLynx is a biotechnology company developing ultra-long-acting therapeutics for obesity and related metabolic diseases. Founded in 2010 by chemists from UCSF, the company's proprietary half-life extension platform enables once-monthly and once-quarterly dosing regimens, improving treatment adherence and tolerability compared to existing obesity drugs. Based in San Francisco, ProLynx raised a $70 million Series A in December 2025.
Summary
Prolynx is a Biotech company based in San Francisco, United States, founded in 2010. It has raised $70.0M in total across 1 round, most recently a $70.0M Series A round in Nov 2025.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2025
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.